Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Транскатетерная или хирургическая замена аортального клапана у пациентов промежуточного риска
2016-04-02
SCID: 54.1/pbf86vsf
Discuss with AI
intermediate-risk patientsnoninferiority trialsevere aortic stenosissurgical aortic-valve replacementtranscatheter aortic-valve replacement
Figures from the paper
Abstract (AI)
BACKGROUND: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement. We evaluated the two procedures in a randomized trial involving intermediate-risk patients. METHODS: We randomly assigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either TAVR or surgical replacement. The primary end point was death from any cause or disabling stroke at 2 years. The primary hypothesis was that TAVR would not be inferior to surgical replacement. Before randomization, patients were entered into one of two cohorts on the basis of clinical and imaging findings; 76.3% of the patients were included in the transfemoral-access cohort and 23.7% in the transthoracic-access cohort. RESULTS: The rate of death from any cause or disabling stroke was similar in the TAVR group and the surgery group (P=0.001 for noninferiority). At 2 years, the Kaplan-Meier event rates were 19.3% in the TAVR group and 21.1% in the surgery group (hazard ratio in the TAVR group, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P=0.25). In the transfemoral-access cohort, TAVR resulted in a lower rate of death or disabling stroke than surgery (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P=0.05), whereas in the transthoracic-access cohort, outcomes were similar in the two groups. TAVR resulted in larger aortic-valve areas than did surgery and also resulted in lower rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation; surgery resulted in fewer major vascular complications and less paravalvular aortic regurgitation. CONCLUSIONS: In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
Key Findings
1
Among transfemoral-access patients, TAVR was associated with fewer deaths or disabling strokes than surgery; transthoracic-access outcomes were similar.
2
In 2032 intermediate-risk patients with severe aortic stenosis, TAVR was noninferior to surgery for death or disabling stroke at two years.
3
Surgery resulted in fewer major vascular complications and less paravalvular aortic regurgitation than TAVR.
4
TAVR provided larger aortic-valve areas and lower rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation.
5
Two-year death or disabling stroke rates were 19.3% with TAVR and 21.1% with surgery (hazard ratio, 0.89; 95% CI, 0.73–1.09).
Research Object
Transcatheter aortic-valve replacement and surgical aortic-valve replacement in intermediate-risk patients with severe aortic stenosis
Research Subject
Comparative clinical outcomes and noninferiority of TAVR versus surgical replacement, including death or disabling stroke and procedure-related complications
Publication Details
Publication Date
2016-04-02
Journal
Publisher
ISSN
Cited by
5138
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by8
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
2017 ESC/EACTS Guidelines for the management of valvular heart disease2017
2021 ESC/EACTS Guidelines for the management of valvular heart disease2021
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients2017
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association2024
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2022
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 20182018